Video

Video Report: A Drug for Ovarian Cancer?

Publish date: June 4, 2011

 

Two trials show bevacizumab delays the progression of ovarian cancer. In this interview, Dr. Andrew Seidman puts the trials into perspective.

Recommended Reading

Half of HIV+ Women in Zambia Positive for Cervical Cancer
MDedge Hematology and Oncology
Fewer Than Half of Ovarian Cancer Patients Get Care Consistent with NCCN Guidelines
MDedge Hematology and Oncology
BRCA2 Gene Mutation Linked With Improved Survival in Ovarian Cancer
MDedge Hematology and Oncology
Gynecologic Cancer Symptoms May Be More Severe in Women With Psychiatric Histories
MDedge Hematology and Oncology
Antiviral Cidofovir May Enhance Therapies for HPV-Related Cancers
MDedge Hematology and Oncology
Symptom Experience in Patients with Gynecological Cancers: The Development of Symptom Clusters through Patient Narratives
MDedge Hematology and Oncology
PARP Inhibitor Olaparib Delays Progression in Ovarian Cancer
MDedge Hematology and Oncology
Three-Year Interval Safe for Cervical Cancer Screening after Negative HPV Test
MDedge Hematology and Oncology
Screening Does Not Reduce Ovarian Cancer Mortality
MDedge Hematology and Oncology
Screening Does Not Reduce Ovarian Cancer Mortality
MDedge Hematology and Oncology